Cargando…

Receptor conversion impacts outcomes of different molecular subtypes of primary breast cancer

BACKGROUND: Although the conversion of clinically used breast cancer biomarkers such as estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) between primary tumors and metastatic lesions is well recognized, data on whether receptor conversion has an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhao, Weipeng, Sun, Linlin, Dong, Guolei, Wang, Xiaorui, Jia, Yan, Tong, Zhongsheng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8111518/ https://www.ncbi.nlm.nih.gov/pubmed/33995598 http://dx.doi.org/10.1177/17588359211012982

Ejemplares similares

HAND2-AS1 Works as a ceRNA of miR-3118 to Suppress Proliferation and Migration in Breast Cancer by Upregulating PHLPP2
por: Dong, Guolei, et al.
Publicado: (2020)

Aberrant Regulation of RAD51 Promotes Resistance of Neoadjuvant Endocrine Therapy in ER-positive Breast Cancer
por: Jia, Yan, et al.
Publicado: (2019)

The mixed subtype has a worse prognosis than other histological subtypes: a retrospective analysis of 217 patients with metaplastic breast cancer
por: Hu, Jiayue, et al.
Publicado: (2023)

Clinical significance and prognostic value of receptor conversion after neoadjuvant chemotherapy in breast cancer patients
por: He, Yang, et al.
Publicado: (2023)

Ribosome Proteins Represented by RPL27A Mark the Development and Metastasis of Triple-Negative Breast Cancer in Mouse and Human
por: Zhao, Weipeng, et al.
Publicado: (2021)

Impact of Molecular Subtype Conversion of Breast Cancers after Neoadjuvant Chemotherapy on Clinical Outcome
por: Lim, Siew Kuan, et al.
Publicado: (2016)

SCD5 expression correlates with prognosis and response to neoadjuvant chemotherapy in breast cancer
por: Zhao, Weipeng, et al.
Publicado: (2021)

Analysis of Clinical Characteristics, Treatment, and Prognostic Factors of 106 Breast Cancer Patients With Solitary Pulmonary Nodules
por: He, Lihong, et al.
Publicado: (2022)

De novo metastatic breast cancer: Subgroup analysis of molecular subtypes and prognosis
por: Zhang, Li, et al.
Publicado: (2020)

MiR-223-3p targeting epithelial cell transforming sequence 2 oncogene inhibits the activity, apoptosis, invasion and migration of MDA-MB-468 breast cancer cells
por: Wang, Xiaorui, et al.
Publicado: (2019)

Molecular Subtype Conversion between Primary and Metastatic Breast Cancer Corresponding to the Dynamics of Apoptotic and Intact Circulating Tumor Cells
por: Stefanovic, Stefan, et al.
Publicado: (2019)

Distinct outcomes in patients with different molecular subtypes of inflammatory breast cancer
por: Zhou, Jingyu, et al.
Publicado: (2014)

Cardiac safety analysis of anti-HER2-targeted therapy in early breast cancer
por: Zhang, Li, et al.
Publicado: (2022)

«Salivaomics» of Different Molecular Biological Subtypes of Breast Cancer
por: Bel’skaya, Lyudmila V., et al.
Publicado: (2022)

Molecular subtype conversion in CTCs as indicator of treatment adequacy associated with metastasis-free survival in breast cancer
por: Grigoryeva, E. S., et al.
Publicado: (2022)

The different prognostic impact of age according to individual molecular subtypes in breast cancer
por: Kim, Nam Hee, et al.
Publicado: (2022)

Expression of Neuroendocrine Markers in Different Molecular Subtypes of Breast Carcinoma
por: Wachter, David L., et al.
Publicado: (2014)

Geographic differences in the distribution of molecular subtypes of breast cancer in Brazil
por: Carvalho, Filomena M, et al.
Publicado: (2014)

Preclinical Advances in Theranostics for the Different Molecular Subtypes of Breast Cancer
por: Fang, Hanyi, et al.
Publicado: (2021)

The Distribution and Outcomes of the 21-Gene Recurrence Score in T1-T2N0 Estrogen Receptor-Positive Breast Cancer With Different Histologic Subtypes
por: Wang, Jun, et al.
Publicado: (2018)

Expression of the Androgen Receptor and its Correlation with Molecular Subtypes in 980 Chinese Breast Cancer Patients
por: Qi, Ji-ping, et al.
Publicado: (2011)

Significance of ERβ expression in different molecular subtypes of breast cancer
por: Guo, Liying, et al.
Publicado: (2014)

Effectiveness of Organized Mammography Screening for Different Breast Cancer Molecular Subtypes
por: Ding, Lilu, et al.
Publicado: (2022)

Decreasing Eukaryotic Initiation Factor 3C (EIF3C) Suppresses Proliferation and Stimulates Apoptosis in Breast Cancer Cell Lines Through Mammalian Target of Rapamycin (mTOR) Pathway
por: Zhao, Weipeng, et al.
Publicado: (2017)

Genomic analysis of pancreatic cancer reveals 3 molecular subtypes with different clinical outcomes
por: Hwang, Ji Woong, et al.
Publicado: (2021)

The prognostic impact of age in different molecular subtypes of breast cancer: a population-based study
por: Dai, Dongjun, et al.
Publicado: (2019)

Parity-related molecular signatures and breast cancer subtypes by estrogen receptor status
por: Rotunno, Melissa, et al.
Publicado: (2014)

The Clinicopathological Features and Survival Outcomes of Different Histological Subtypes in Triple-negative Breast Cancer
por: Liao, Hong-Ye, et al.
Publicado: (2018)

Metaplastic breast cancer: Treatment and prognosis by molecular subtype
por: Hu, Jin, et al.
Publicado: (2021)

Breast cancer in Ethiopia: evidence for geographic difference in the distribution of molecular subtypes in Africa
por: Hadgu, Endale, et al.
Publicado: (2018)

Molecular subtypes of triple-negative breast cancer in women of different race and ethnicity
por: Ding, Yuan Chun, et al.
Publicado: (2019)

Prognostic Value of Clinicopathological Factors for Indonesian Breast Carcinomas of Different Molecular Subtypes
por: Widodo, Irianiwati, et al.
Publicado: (2017)

Correlation between the CEM imaging characteristics and different molecular subtypes of breast cancer
por: Li, Na, et al.
Publicado: (2023)

Impact of mRNA-Assessed Molecular Subtype Conversion, Intact and Apoptotic Circulating Tumor Cells on Survival of Metastatic Breast Cancer Patients: Proof of Principle
por: Stefanovic, Stefan, et al.
Publicado: (2020)

Characteristics and survival of patients with metachronous or synchronous double primary malignancies: breast and thyroid cancer
por: Zhang, Li, et al.
Publicado: (2016)

Clinical evaluation of molecular surrogate subtypes in patients with ipsilateral multifocal primary breast cancer
por: Janeva, Slavica, et al.
Publicado: (2023)

Negative Conversion of Progesterone Receptor Status after Primary Systemic Therapy Is Associated with Poor Clinical Outcome in Patients with Breast Cancer
por: Ahn, Soomin, et al.
Publicado: (2018)

Molecular subtypes and precision treatment of triple-negative breast cancer
por: Zhao, Shen, et al.
Publicado: (2020)

Association of sonographic features and molecular subtypes in predicting breast cancer disease outcomes
por: Wang, Haoyu, et al.
Publicado: (2020)

Long-term outcomes of non-metastatic breast cancer patients by molecular subtypes
por: Fendereski, Afsaneh, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_97mrh755oq6oobh065d947ktqd